Borghese Ottavia, Pascucci Domenico, Peluso Nicolò, Sposato Francesco, Marzullo Antonino, Donati Tommaso, Rascio Laura, Tshomba Yamume
Unit of Vascular Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Section of Hygiene, Department of Life Science and Public Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
J Clin Med. 2025 May 9;14(10):3296. doi: 10.3390/jcm14103296.
Popliteal venous aneurysms (PVA) are an uncommon but potentially severe condition due to their association with increased risk of recurrent pulmonary embolisms. Because of their rarity, their aetiology, natural history, and optimal treatment strategies have been poorly defined. The aim of this paper is to report a comprehensive systematic review on the treatment strategies and outcomes in PVA, summarizing current evidence. A systematic literature search was conducted in PubMed, Scopus, and Web of Science, covering studies published from database inception through February 2025 (protocol registered on PROSPERO CRD420251008927). The primary endpoint was the analysis of outcomes and complications associated with surgical and conservative management. Nine studies, including 173 adult patients with popliteal venous aneurysms, were included. The mean age was 56 years (range 18-86 years, mean aneurysm diameter 25.4 mm). Most of the patients were female (73, 42.2%). Overall, 85 (49.1%) aneurysms were saccular and 74 (42.8%) fusiform, although morphology was not consistently reported across all studies. Intraluminal thrombus was reported in 26 cases (15.0%), and pulmonary embolism upon presentation in 21 (12.1%). Surgical treatment was performed in 119 patients (68.8%), while 54 (31.2%) were managed conservatively. Fifteen patients (13.0%) experienced postoperative complications, including wound infections (4, 3.5%), hematomas (7, 6.0%), and nerve injury (4, 3.5%), but no cases of postoperative pulmonary embolisms were observed. Following surgery, anticoagulation was indicated in most cases for 3-6 months or a long life. During follow-up (mean 35 months, range 1-262), thrombosis of the surgical reconstruction was observed in 1 patient (0.8%). Death occurred in 3 cases (5.5%), all in the non-surgical group: 2 (3.7%) due to malignancy and 1 (1.9%) from myocardial infarction. PVA is a rarely described condition potentially associated with the risk of PE. In their management, surgical strategies in association with oral anticoagulation represent the most commonly described approach, allowing for satisfactory results and a low rate of complications.
腘静脉动脉瘤(PVA)并不常见,但因其与复发性肺栓塞风险增加相关,故可能是一种严重疾病。由于其罕见性,其病因、自然史及最佳治疗策略尚未明确界定。本文旨在报告一项关于PVA治疗策略及结果的全面系统评价,总结当前证据。在PubMed、Scopus和Web of Science中进行了系统的文献检索,涵盖从数据库建立至2025年2月发表的研究(方案已在PROSPERO注册,注册号CRD420251008927)。主要终点是分析与手术及保守治疗相关的结果和并发症。纳入了9项研究,包括173例患有腘静脉动脉瘤的成年患者。平均年龄为56岁(范围18 - 86岁,平均动脉瘤直径25.4mm)。大多数患者为女性(73例,42.2%)。总体而言,85个(49.1%)动脉瘤为囊状,74个(42.8%)为梭形,不过并非所有研究都一致报告了形态。26例(15.0%)报告有腔内血栓形成,21例(12.1%)就诊时即有肺栓塞。119例患者(68.8%)接受了手术治疗,54例(31.2%)接受了保守治疗。15例患者(13.0%)出现术后并发症,包括伤口感染(4例,3.5%)、血肿(7例,6.0%)和神经损伤(4例,3.5%),但未观察到术后肺栓塞病例。手术后,大多数病例需抗凝3 - 6个月或终身抗凝。在随访期间(平均35个月,范围1 - 262个月),1例患者(0.8%)出现手术重建处血栓形成。3例患者(5.5%)死亡,均在非手术组:2例(3.7%)死于恶性肿瘤,1例(1.9%)死于心肌梗死。PVA是一种很少被描述的疾病,可能与肺栓塞风险相关。在其治疗中,手术策略联合口服抗凝是最常描述的方法,可取得满意效果且并发症发生率低。